- Home
- REAL vs ACIU Comparison
REAL vs ACIU Comparison
Compare REAL & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REAL
- ACIU
- Stock Information
- Founded
- REAL 2011
- ACIU 2003
- Country
- REAL United States
- ACIU Switzerland
- Employees
- REAL N/A
- ACIU N/A
- Industry
- REAL Other Specialty Stores
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- REAL Consumer Discretionary
- ACIU Health Care
- Exchange
- REAL Nasdaq
- ACIU Nasdaq
- Market Cap
- REAL 641.9M
- ACIU 189.1M
- IPO Year
- REAL 2019
- ACIU 2016
- Fundamental
- Price
- REAL $5.31
- ACIU $2.07
- Analyst Decision
- REAL Buy
- ACIU Strong Buy
- Analyst Count
- REAL 5
- ACIU 1
- Target Price
- REAL $8.40
- ACIU $12.00
- AVG Volume (30 Days)
- REAL 3.0M
- ACIU 139.5K
- Earning Date
- REAL 08-05-2025
- ACIU 08-05-2025
- Dividend Yield
- REAL N/A
- ACIU N/A
- EPS Growth
- REAL N/A
- ACIU N/A
- EPS
- REAL N/A
- ACIU N/A
- Revenue
- REAL $616,717,000.00
- ACIU $32,014,254.00
- Revenue This Year
- REAL $11.70
- ACIU N/A
- Revenue Next Year
- REAL $10.10
- ACIU $533.21
- P/E Ratio
- REAL N/A
- ACIU N/A
- Revenue Growth
- REAL 11.89
- ACIU 91.20
- 52 Week Low
- REAL $2.24
- ACIU $1.43
- 52 Week High
- REAL $11.38
- ACIU $4.26
- Technical
- Relative Strength Index (RSI)
- REAL 52.98
- ACIU 56.20
- Support Level
- REAL $4.71
- ACIU $1.65
- Resistance Level
- REAL $5.30
- ACIU $2.17
- Average True Range (ATR)
- REAL 0.26
- ACIU 0.17
- MACD
- REAL 0.04
- ACIU -0.01
- Stochastic Oscillator
- REAL 100.00
- ACIU 70.37
About REAL The RealReal Inc.
The RealReal is the largest pure-play luxury resale platform in the US, generating $1.8 billion in 2024 gross merchandise volume and addressing a niche (personal luxury resale) that had previously been serviced by inefficient upscale boutiques and local pawn shops. The company generates revenue via consignment and first-party sales on its online marketplace, and through a small volume of direct sales. With a hands-on approach that actively sources inventory and authenticates every item on its platform, The RealReal is able to justify much higher take rates than peers, working out to roughly 36% of net merchandise value in 2024, which excludes returns, cancellations, and first-party sales.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.